Tango Therapeutics Files Proxy Materials for 2025 Meeting

Ticker: TNGX · Form: DEFA14A · Filed: Apr 22, 2025 · CIK: 1819133

Sentiment: neutral

Topics: proxy-statement, annual-meeting, regulatory-filing

TL;DR

Tango Therapeutics filed proxy docs for their 2025 meeting, no fee needed.

AI Summary

Tango Therapeutics, Inc. filed a Definitive Additional Materials proxy statement on April 22, 2025, related to its 2025 Annual Meeting. The filing indicates no fee was required for this submission. Tango Therapeutics, Inc. is a pharmaceutical preparations company incorporated in Delaware.

Why It Matters

This filing provides shareholders with important information regarding the upcoming annual meeting, allowing them to exercise their voting rights on company matters.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement for an annual meeting and does not contain information that inherently increases risk for investors.

Key Numbers

Key Players & Entities

FAQ

What type of filing is this?

This is a Definitive Additional Materials filing (DEFA14A) for Tango Therapeutics, Inc.

When was this filing made?

The filing was made on April 22, 2025.

Is there a fee associated with this filing?

No fee was required for this filing.

What is the company's former name?

The company's former name was BCTG Acquisition Corp., with a date of name change on July 23, 2020.

What is the company's primary business?

The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].

Filing Details

This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 22, 2025 regarding Tango Therapeutics, Inc. (TNGX).

View full filing on EDGAR

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on Read The Filing